Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from GlaxoSmithKline and Oncopeptides.

Targeting Treatment in Relapsed/Refractory Multiple Myeloma: Experts Discuss Novel Agents, Combinations, and Ongoing Trials

Release Date: September 3, 2020
Expiration Date: September 3, 2021

Activity Overview

The treatment landscape for relapsed/refractory multiple myeloma (R/R MM) has evolved rapidly due to an enhanced understanding of the heterogeneous nature of the disease. As novel targeted therapies emerge in the frontline and relapsed settings, clinicians are frequently unsure of how to choose the optimal therapy based on patient- and disease-related factors, and how to combine and sequence therapies to improve patient outcomes. This webcast will provide insights on these topics by providing updates on the latest clinical data on therapies in R/R MM, and by offering guidance on sequencing therapies.

Acknowledgment of Commercial Support

This activity is supported by educational grants from GlaxoSmithKline and Oncopeptides.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward hematologists, and medical oncologists who treat patients with MM. Nurses, nurse practitioners, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of MM will be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Summarize safety and efficacy data from recent clinical trials in relapsed/refractory multiple myeloma
  • Explain mechanisms of action of novel investigational therapies and the rationale supporting their utility in the treatment of patients with R/R MM
  • Select optimal therapies for patients with R/R MM based on disease, treatment, and patient-related factors

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Balazs Halmos, MD, MS
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, GA

Disclosures: Consultant: Merck, Novartis, Onyx, Millennium, Bristol Myers Squibb, Sanofi, Celgene, Janssen


Nikhil C. Munshi, MD
Nikhil C. Munshi, MD
Kraft Family Chair
Director, Basic and Correlative Sciences
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Disclosures: Consultant: AbbVie, Adaptive, Amgen, BeiGene, Bristol Myers Squibb, Celgene, Janssen, Karyopharm, Takeda, OncoPep Shareholder: OncoPep Other: OncoPep (ownership)

Nina Shah, MD, MPH
Nina Shah, MD
Associate Professor
Division of Hematology-Oncology
University of California San Francisco
San Francisco, CA

Disclosures: Grant/Research Support: Bluebird Bio, Celgene/Bristol Myers Squibb, Janssen, Nektar, Poseida, Sutro Biopharma, TeneoBio Consultant: Amgen, Bristol Myers Squibb, CareDx, GlaxoSmithKline, Indapta Therapeutics, Karyopharm, Kite, Sanofi

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By